Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.FDA approves CollaGenex rosacea drug
Oracea is the first FDA-approved, orally-administered, systemically-delivered drug to treat rosacea, a dermatologic condition that affects an estimated 14 million adults in the US. CollaGenex said that it
Oracea is the first FDA-approved, orally-administered, systemically-delivered drug to treat rosacea, a dermatologic condition that affects an estimated 14 million adults in the US. CollaGenex said that it
The agreement allows Isis to sell registered shares of its common stock at a small discount to the market price to Azimuth Opportunity over the next 18 months.
Research conducted by Ambrilia’s collaborators and scientists has revealed that PCK3145, an anticancer synthetic peptide, binds to the cell surface laminin receptor and triggers a signaling cascade of
The study, a phase II double-blind, placebo controlled, multi-dose study in treatment-experience HIV patients, assessed SP01A’s safety and effect on viral load in HIV-1 positive individuals, with evidence
The transaction, which involved purchasing the outstanding 16.66% shares owned by Akzo Nobel’s main partner Chang Cheng Securities, means that the company now wholly owns its powder coatings
During the special protocol assessment (SPA) process, the FDA evaluates the adequacy of the proposed trial’s design to support the efficacy claims that will be part of the
The finding from the study suggests that two drugs in Micromet’s pipeline that target EpCAM may have utility in ovarian cancer. These drugs include the human antibody adecatumumab
Shingles is a frequently painful disease marked by a blistering rash. Caused by the reactivation of the virus that causes chickenpox, shingles can lead to severe complications including
Teva said that final approval of this ANDA is expected in April 2010 when patent protection for the brand product expires. The company last week said that the
A team at the University of California Los Angeles, led by Dr Michael Teitell, and collaborators at Harvard Medical School, The Rockefeller University and the National Institutes of